Gene Editing Stocks Are Worth A Look After Intellia’s Big Breakthrough
- Friday, July 2, 2021, 9:10
- Market
- Add a comment
Intellia Therapeutics – a gene-editing company co-founded by CRISPR pioneer and Nobel prize winner Jennifer Doudna – indicated that NTLA-2001, its experimental treatment for transthyretin amyloidosis provided very promising results in an early state trial. Although the study was small, including…
About the Author
admin123 has written 23527 stories on this site.
